CYTK EVP Malik Fady Ibraham Exercises Options, Sells 3,500 Shares

What Happened

• Malik Fady Ibraham, Executive Vice President, Research & Development at Cytokinetics (CYTK), exercised options and sold shares on 2026-08-18. He exercised 3,500 option-derived shares at an exercise price of $7.80 (cost $27,300) and sold 3,500 shares in an open-market transaction at $75.82 for total proceeds of $265,370. The filing also records a derivative disposition of 3,500 shares at $0 (see context below).
• This transaction is effectively a sale of shares following option exercise (commonly routine liquidity by insiders rather than a public vote of confidence).

Key Details

• Transaction date: 2026-08-18.
• Exercise: 3,500 shares @ $7.80 = $27,300 (code M).
• Sale: 3,500 shares @ $75.82 = $265,370 (code S).
• Derivative disposition: 3,500 shares @ $0 recorded (code M, disposed).
• Shares owned after transaction: Not reported in the provided filing data.
• Filing date vs transaction date: Form filed with period of report 2026-08-18 (no late filing indicated in provided data).
• No 10b5-1 plan, tax-withholding footnotes, or other special plan references were provided in the data supplied.

Context

• Because the option exercise and the open-market sale occurred on the same date for the same share count, this is consistent with a cashless exercise (options exercised and shares immediately sold to realize proceeds). The $0 disposition line often reflects shares withheld or surrendered to cover taxes or option costs in the exercise process; the filing lists it as a derivative disposition rather than an additional market sale.
• Sales by executives are common for tax or diversification reasons; this Form 4 documents the mechanics (exercise + sale) but does not indicate the insider’s view on the company’s prospects.